Binding- and signaling-based grouping of GIPR variants and their respective burden association on cardiometabolic phenotypes in the UK Biobank. Credit: Nature Metabolism (2024). DOI: 10.1038/s42255-024-01061-4 Much like the Cold War space race, the world’s pharmaceutical giants are currently scrambling to produce the best weight-loss drug. They all want to be the first to explore the nooks and crannies of the body in order to be able to design the optimal drug. However, several pharmaceutical giants disagree on what the next step should be. The kernel of the controversy is the Read More